The Rogosin Institute Inc.
New York, NY
- UEI
- RNFSMT79DVD4
- CAGE
- 5DRH0
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 504 E 74th St, New York, NY 10021, USA
- Website
- rogosin.org
- Founded
- 1983
- Employees
- 251-1K
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health Care Services
- SIC code
- 80 Health Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $297,458 |
| FY2025 | $33,713 |
| FY2024 | $168,467 |
| FY2023 | $161,896 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $297,458 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| New York State Division Of Homeland Security & Emergency Services | 4480DRNYP00000001 | $0 | |
| Weill Medical College Of Cornell University | R01DK131050 | $204,876 | |
| New York State Division Of Homeland Security & Emergency Services | 4480DRNYP00000001 | $812,218 | |
| University Of Maryland, Baltimore | U24DK126110 | $63,500 | |
| University Of Washington | U01DK123786 | $31,694 |
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
The Rogosin Institute Inc., a nonprofit organization based in New York City specializing in renal disease research and clinical care, operates as both a prime contractor and sub-recipient on federal awards, delivering human leukocyte antigen (HLA) tissue typing, immunogenetics testing, and kidney research services to the Department of Veterans Affairs and the National Institutes of Health. The institute holds no SBA set-aside designations and competes in full-and-open procurement; its federal footprint is concentrated in specialized medical diagnostics and nephrology research rather than commercial services.
The Rogosin Institute's customer base is heavily concentrated in two agencies. The Department of Veterans Affairs Veterans Integrated Service Network 2 (VA-VHA VISN 2) accounts for 10 awards valued at $5.1 million combined potential value, representing 100% of the institute's contract dollar volume. The National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases accounts for 10 sub-grant awards, with the Federal Emergency Management Agency Headquarters contributing 2 sub-grant awards. A single award from the Defense Health Agency and one from the National Institute on Drug Abuse round out the agency roster.
As a prime contractor, the Rogosin Institute holds a $2 million indefinite-delivery contract with VA-VHA VISN 2 (awarded June 1, 2026, running through May 31, 2031) to provide tissue typing and immunogenetics testing for kidney transplant matching for veterans in the New York City area, with place of performance in the Bronx. Six delivery orders under a predecessor IDC (36C24221D0022) carry $1.5 million in combined potential value; a seventh delivery order issued June 1, 2026, under the new IDC carries $390,610 with ultimate completion May 31, 2027. Earlier task orders include a $122,200 award (December 1, 2024), a $102,926 award (December 1, 2023), a $113,542 award (December 1, 2022), and a $161,942 award (December 1, 2021), all for renal transplant program immunogenetics and tissue typing services. Combined obligated dollars across all awards total $24.9 million against $5.1 million in combined potential value, reflecting multi-year renewal and extension patterns.
On the grant side, the Rogosin Institute serves as a sub-recipient under multiple prime grantees. It participates as an active research member in the (Re)Building a Kidney Consortium coordinated by the Mount Desert Island Biological Laboratory (sub-awards June 1, 2022; June 1, 2023; and June 28, 2024), advancing ex vivo kidney organogenesis for renal replacement therapy. The institute also recruits clinical trial participants for pain management in dialysis patients under a Weill Medical College of Cornell University sub-award (March 27, 2025) and serves as a coordinating site for the Polycystic Kidney Disease Research and Translation Core Centers under University of Maryland, Baltimore sub-awards (April 1, 2024, and September 17, 2024). Sub-awards for randomized end-stage renal disease trials (July 31, 2024) and COVID-19 and emergency management cost reimbursement (January 30, 2025, and April 17, 2025) complete the recent grant portfolio. Only two awards in the next twenty-four months face recompete, with a combined potential value of $391 thousand. Award activity has averaged two to five per year over the past five years, with recent trajectory flat.
Quick answers
Is The Rogosin Institute Inc. registered in SAM.gov?
Yes. The Rogosin Institute Inc.'s SAM.gov registration is active through March 31, 2027.
How much has The Rogosin Institute Inc. received in federal contracts?
Federal contracts obligated $33,713 to The Rogosin Institute Inc. in fiscal year 2025 and $661,533 in fiscal years 2023 through 2027.
How does The Rogosin Institute Inc. rank among federal contractors?
The Rogosin Institute Inc. ranked #65 in PSC Q515 in FY2025.
What is The Rogosin Institute Inc.'s most recent federal award?
The Rogosin Institute Inc.'s most recent federal contract award is Testing is essential to properly match organ donors with recipients, to decrease rejection and increase longevity of… (36C24226N0461), from Veterans Integrated Service Network 2 (VHA), on June 1, 2026.
On GovTribe
See The Rogosin Institute Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors